主要文件

查看所有文档

SML4254

AT7519

Name: AT7519
Brand: SIGMA

≥98% (HPLC), powder, CDK inhibitor

别名:

AT 7519, AT-7519, AT7519, N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide, 4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide, 4-[(2,6-Dichlorobenzoyl)amino]-N-4-piperidinyl-1H-pyrazole-3-carboxamide

登录并加购，请在购物车里查看协议价、货期和发货地。

选择规格

变更视图

关于此项目

经验公式（希尔记法）:

C₁₆H₁₇Cl₂N₅O₂

化学文摘社编号:

844442-38-2

分子量:

382.24

MDL number:

MFCD28977942

NACRES:

NA.21

Assay:

≥98% (HPLC)

Form:

powder

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Segment

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

说明

Application

AT7519 may be used to study its effects on cell viability and proliferation, cell cycle, apoptosis and pyroptosis in human glioblastoma cells.

Biochem/physiol Actions

AT7519 is a potent and selective cyclin dependent kinase (CDK) inhibitor (CDK5-p35/CDK2-CycA/CDK4-CycD1/CDK1-CycB IC50 = 18/44/67/190 nM; IC50 >10 μM against Aurora A, IR, MEK1, PDK1, c-abl) with antiproliferative activity in cancer cultures (IC50 = 82 nM/HCT116, 350 nM/A2780) and antitumor efficacy in mice in vivo (86% inhibition of A2780 xenograft tumor growth post 8-day treatment at 7.5 mg/kg b.i.d. i.p., 87% inhibition of HCT116 xenograft tumor growth post 10-day treatment at 9.1 mg/kg b.i.d. i.p.).

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库